The Indian Competition Authority approves the acquisition of the Asian marketing subsidiary of a major pharmaceutical company by its UK and global healthcare subsidiaries (GSK Healthcare Overseas / GSK Healthcare UK / GSK Asia)

GlaxoSmithKline Consumer Healthcare Overseas Limited (“GSK Healthcare overseas”) and GlaxoSmithKline Consumer Healthcare UK Trading Limited (“GSK Healthcare UK”), (collectively referred to as “Acquirers”) are wholly owned subsidiaries of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited (“GSK Healthcare HoldCo”). GSK Healthcare HoldCo was established through the contribution by GlaxoSmithKline plc. (“GSK”) and Pfizer Inc. (“Pfizer”) of their respective legacy consumer healthcare businesses and is owned 68% by GSK and 32% by Pfizer. GlaxoSmithKline Asia Private Limited (“GSK Asia”), a subsidiary of GlaxoSmithKline Pte. Ltd. (“GSK Pte.”), is involved in the marketing and distribution of over the counter (“OTC”) oral consumer healthcare products under various brand names such as ‘Parodontax’,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Neelambera Sandeepan, L. Badri Narayanan, Charanya Lakshmikumaran, The Indian Competition Authority approves the acquisition of the Asian marketing subsidiary of a major pharmaceutical company by its UK and global healthcare subsidiaries (GSK Healthcare Overseas / GSK Healthcare UK / GSK Asia), 21 January 2022, e-Competitions January 2022, Art. N° 106177

Visites 134

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues